Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study

被引:0
作者
Erik D. Storholm
Jonathan E. Volk
Julia L. Marcus
Michael J. Silverberg
Derek D. Satre
机构
[1] RAND Corporation,Department of Psychiatry
[2] Kaiser Permanente Northern California,undefined
[3] Division of Research,undefined
[4] University of California,undefined
[5] Kaiser Permanente Medical Center,undefined
来源
Prevention Science | 2017年 / 18卷
关键词
Pre-exposure prophylaxis; PrEP; Adherence; Risk perception; Sexual behavior; Alcohol; Methamphetamine; Substance use;
D O I
暂无
中图分类号
学科分类号
摘要
The antiretroviral drug combination emtricitabine and tenofovir disoproxil fumarate (TDF/FTC) taken as pre-exposure prophylaxis (PrEP) is effective in preventing HIV infection, yet it also requires adherence and potentially decreases condom use. This study sought to examine these issues among a key population at risk of HIV infection, substance-using men who have sex with men (MSM). We conducted semi-structured interviews with an ethnically diverse sample of 30 young (aged 20–35) MSM prescribed PrEP within a large integrated healthcare system in San Francisco, who had reported recent drug use or hazardous drinking and one or more missed doses of PrEP. We explored participants’ risk perception and sexual risk behavior, drug and alcohol use, and PrEP adherence in the context of substance use. Interviews were transcribed and coded using a directed content analysis approach to identify key categories and commonalities, and differences across participants. Salient subcategories included positive psychological effects of being on PrEP (e.g., decreased anxiety, feelings of empowerment), social effects (e.g., reduced HIV stigma), and reduction in overall perceptions of HIV risk. While overall reported use of condoms went down and many reported a brief period of increased condomless sex following PrEP initiation, others continued condom use with most of their sexual partners. Contextual factors influencing their decision to engage in condomless sex included how well they knew the partner and whether the partner was on PrEP or HIV antiretroviral treatment. Factors associated with poor adherence included disruptions in daily routine and use of alcohol and methamphetamine. PrEP-prescribing clinicians should support their patients in making informed decisions about condom use and identifying strategies to maximize adherence in the context of substance use.
引用
收藏
页码:737 / 747
页数:10
相关论文
共 151 条
[1]  
Abbas UL(2011)Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis PrEP PloS One 6 178-193
[2]  
Hood G(2010)A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization Drug and Alcohol Dependence 112 193-410
[3]  
Wetzel AW(2015)Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: A longitudinal analysis BMC Infectious Diseases 15 399-1145
[4]  
Mellors JW(2012)Antiretroviral prophylaxis for HIV prevention in heterosexual men and women New England Journal of Medicine 367 1136-1048
[5]  
Azar MM(2011)Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships AIDS Care 23 1040-1469
[6]  
Springer SA(2015)Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles International Journal of STD & AIDS 26 1461-607
[7]  
Meyer JP(2016)Sexual behavior, risk compensation, and HIV prevention strategies among participants in the San Francisco PrEP Demonstration Project: A qualitative analysis of counseling notes AIDS and Behavior 20 605-156
[8]  
Altice FL(2006)Risk compensation: The Achilles’ heel of innovations in HIV prevention? BMJ (Clinical Research Ed.) 332 144-348
[9]  
Azar P(2011)Defining risk drinking Alcohol Research and Health 34 340-1826
[10]  
Wood E(2014)HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention Journal of Acquired Immune Deficiencies Syndrome 66 1820-555